EC pushes for speedier drug decisions

Friday 9 March 2012

Plans to streamline and speed up national drug pricing and reimbursement decisions have been laid out by the European Commission.

In an update to its Transparency Directive it wants decisions to be taken within 120 days for innovative medicines and 30 days for generic drugs - the current time limit for both is 180 days.

The commission is also proposing stronger enforcement measures to ensure compliance by the member states with the potential new time limits, as the current deadlines are frequently exceeded.

The proposals follow the EC's 2009 pharma inquiry, which found that delays in national pricing and reimbursement decisions could be as long as 700 days for innovative drugs and up to 250 days for generics.

Both the European Generic Medicines Association and the European Federation of Pharmaceutical Industries and Associations broadly supported the ideas, although each has put forward amendments.

Your page is loading. Please wait...